PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase‐1 by a mechanism dependent on MAP kinase phosphatase‐1

Phosphodiesterase‐4 (PDE4) inhibitors have recently been introduced to the treatment of COPD and psoriatic arthritis. Microsomal prostaglandin E synthase‐1 (mPGES‐1) is an inducible enzyme synthesizing PGE (2), the most abundant prostanoid related to inflammation and inflammatory pain. mPGES‐1 is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuure, Lauri, Hämäläinen, Mari, Moilanen, Eeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723697/
https://www.ncbi.nlm.nih.gov/pubmed/29226622
http://dx.doi.org/10.1002/prp2.363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723697/
https://www.ncbi.nlm.nih.gov/pubmed/29226622
http://dx.doi.org/10.1002/prp2.363

Ejemplares similares